In 2024, the Environmental Protection Agency finalised a rule banning chrysotile asbestos — the only form still commercially imported into the United States. The rule was immediately challenged in court by industry groups who argued, among other things, that chrysotile poses meaningfully less risk than other forms of asbestos and that a ban was therefore disproportionate to the actual hazard.
This argument — that chrysotile is the “safe” or “safer” form of asbestos — has been the asbestos industry’s primary scientific lobbying strategy for fifty years. It has been funded by asbestos mining interests, deployed in regulatory proceedings, and cited in congressional testimony. Understanding how it was constructed, who paid for it, and what the science actually says is essential to understanding the asbestos policy debate in 2026.
The Science
The International Agency for Research on Cancer classifies all forms of asbestos — chrysotile, crocidolite, amosite, anthophyllite, tremolite, and actinolite — as Group 1 carcinogens. Group 1 is the highest category: sufficient evidence of carcinogenicity in humans.
Epidemiological studies document mesothelioma in populations exposed exclusively to chrysotile, with no amphibole exposure. The chrysotile defence rests in part on the observation that chrysotile fibres are more readily cleared from the lung than amphibole fibres — chrysotile is a serpentine mineral with curly fibres, while amphiboles have straight, needle-like fibres that lodge more persistently in lung tissue. The industry argument is that this difference in biopersistence means chrysotile poses lower risk.
The scientific consensus does not support using this distinction as a basis for different regulatory treatment. Chrysotile fibres, though more readily cleared than amphiboles, are still retained long enough to cause cancer in exposed populations at occupational concentrations. Published studies of chrysotile textile workers, chrysotile miners, and populations exposed to chrysotile-containing consumer products all document elevated mesothelioma rates.
If This Investigation Affects You
The chrysotile debate does not affect your legal rights. If you were exposed to chrysotile asbestos products — brake pads, insulation, floor tiles, joint compound — and have been diagnosed with mesothelioma, the manufacturers of those products established trust funds to compensate you. The scientific dispute over relative risk was a lobbying strategy. The trust funds exist regardless of its outcome.
Trust fund claims are generally subject to statutes of limitations of 1 to 3 years from the date of diagnosis, varying by state. Acting now preserves your options.
Get a Free Confidential Case Review →
No obligation. No upfront cost. Initial communications are confidential. Attorney advertising.
The Funded Research Network
The chrysotile defence was not an organic scientific consensus. It was the product of a sustained, funded research programme — coordinated by asbestos mining interests and their lobbying arms — designed to create and maintain scientific ambiguity about chrysotile’s risk profile.
The Quebec Asbestos Mining Association, which represented Canadian chrysotile producers who exported heavily to the US and other markets, funded a network of scientists whose work consistently produced results more favourable to the chrysotile industry than the work of independent researchers. The Chrysotile Institute — established after the QAMA was dissolved — continued this work through the 2000s.
Documents obtained through litigation and regulatory proceedings show consistent patterns: researchers who received industry funding published studies with conclusions more favourable to chrysotile than the same researchers’ unpublished internal assessments, unfavourable results were not submitted for publication, and researchers who produced unfavourable findings faced loss of funding.
The Regulatory Impact
The chrysotile defence succeeded, for several decades, in maintaining sufficient scientific ambiguity to prevent decisive regulatory action. When EPA issued its comprehensive asbestos ban in 1989, the industry’s legal challenge — which succeeded in the Fifth Circuit two years later — relied in part on arguments that EPA had not adequately accounted for differences between chrysotile and amphibole forms.
In subsequent Congressional hearings on asbestos legislation, industry representatives consistently invoked the chrysotile distinction to argue that a comprehensive ban was scientifically unjustified. The argument created enough uncertainty that legislative majorities for a ban repeatedly failed to form.
The 2024 EPA chrysotile ban — and the industry’s immediate legal challenge to it — represents the latest round of this fifty-year dispute. The science has not changed in a way that supports the industry’s position. What has changed is the regulatory framework, and the willingness of EPA to act under the reformed TSCA standard.
What This Means for Claimants
The chrysotile debate is entirely irrelevant to trust fund eligibility. The trust funds established by chrysotile product manufacturers — including the Manville trust, the Armstrong trust, and others — do not distinguish between chrysotile and amphibole exposure in their eligibility criteria. If you were exposed to a covered product and have a qualifying diagnosis, the trust fund applies. The scientific dispute over relative risk was a lobbying strategy, not a legal determination.
More from The Asbestos Files